1429505-03-2

Usage

Uses

Used in Coordination Chemistry:
(4-benzyl-4-hydroxypiperidin-1-yl)(2,4′-bipyridin-3-yl)-methanone is used as a ligand for metal ions or transition metals in coordination chemistry, due to its 2,4'-bipyridine ring's potential ability to bind with these elements.
Used in Catalysis:
In the field of catalysis, (4-benzyl-4-hydroxypiperidin-1-yl)(2,4′-bipyridin-3-yl)-methanone is used as a catalyst or a component of a catalytic system, potentially leveraging its metal-binding properties to facilitate chemical reactions.
Used in Metal-Based Drug Design:
(4-benzyl-4-hydroxypiperidin-1-yl)(2,4′-bipyridin-3-yl)-methanone is used as a ligand in the design of metal-based drugs, where its ability to chelate with metal ions could be harnessed for therapeutic purposes.
Further research and experimentation are required to fully explore the properties and potential applications of this chemical compound.

Upstream product

• 121495-79-2 2-chloropyridine-3-carbonyl chloride hydrochloride 
• 65-85-0 benzoic acid 
• 49609-84-9 2-Chloronicotinoyl chloride 
• 2942-59-8 2-chloronicotinic acid 
• 1429505-87-2 (4-benzyl-4-hydroxypiperidin-1-yl)(2-chloropyridin-3-yl)-methanone 
• 1692-15-5 4-pyridylboronic acid 
• 51135-96-7 4-benzyl-4-hydroxypiperidine 

Relevant academic research and scientific papers

Discovery of Soticlestat, a Potent and Selective Inhibitor for Cholesterol 24-Hydroxylase (CH24H)

Cholesterol 24-hydroxylase (CH24H, CYP46A1), a brain-specific cytochrome P450 (CYP) family enzyme, plays a role in the homeostasis of brain cholesterol by converting cholesterol to 24S-hydroxycholesterol (24HC). Despite a wide range of potential of CH24H as a drug target, no potent and selective inhibitors have been identified. Here, we report on the structure-based drug design (SBDD) of novel 4-arylpyridine derivatives based on the X-ray co-crystal structure of hit derivative 1b. Optimization of 4-arylpyridine derivatives led us to identify 3v ((4-benzyl-4-hydroxypiperidin-1-yl)(2,4′-bipyridin-3-yl)methanone, IC50 = 7.4 nM) as a highly potent, selective, and brain-penetrant CH24H inhibitor. Following oral administration to mice, 3v resulted in a dose-dependent reduction of 24HC levels in the brain (1, 3, and 10 mg/kg). Compound 3v (soticlestat, also known as TAK-935) is currently under clinical investigation for the treatment of Dravet syndrome and Lennox-Gastaut syndrome as a novel drug class for epilepsies.

METHOD FOR PRODUCING HETEROCYCLIC COMPOUND

The present invention provides a production method of heterocyclic compound having an excellent CH24H inhibitory action, which is suitable for industrial production. In the present invention, a 2-halogenonicotinic acid or a reactive derivative thereof or a salt thereof is reacted with 4-benzyl-4-hydroxypiperidine acid addition salt to give a (4-benzyl-4-hydroxypiperidin-1-yl) (2-halogenopyridin-3-yl)methanone or a salt thereof, and then the obtained compound is reacted with pyridine-4-boronic acid or a reactive derivative thereof or a salt thereof in the presence of a metal catalyst and a base to give (4-benzyl-4-hydroxypiperidin-1-yl) (2,4′-bipyridin-3-yl)methanone or a salt thereof.

HETEROCYCLIC COMPOUNDS

The present invention provides a compound useful as an agent for the prophylaxis or treatment of neurodegenerative disease and the like, or a salt thereof. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.